DK1443955T3 - PDGF-BB til behandling af Parkinsons sygdom - Google Patents
PDGF-BB til behandling af Parkinsons sygdomInfo
- Publication number
- DK1443955T3 DK1443955T3 DK02798797.3T DK02798797T DK1443955T3 DK 1443955 T3 DK1443955 T3 DK 1443955T3 DK 02798797 T DK02798797 T DK 02798797T DK 1443955 T3 DK1443955 T3 DK 1443955T3
- Authority
- DK
- Denmark
- Prior art keywords
- pdgf
- parkinson
- disease
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/49—Platelet-derived growth factor [PDGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Analytical Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32338101P | 2001-09-19 | 2001-09-19 | |
US32604401P | 2001-09-28 | 2001-09-28 | |
PCT/IB2002/003998 WO2003024478A1 (en) | 2001-09-19 | 2002-09-19 | Treatment of central nervous system disorders by use of pdgf or vegf |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1443955T3 true DK1443955T3 (da) | 2013-01-02 |
Family
ID=26983933
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10179127.5T DK2266594T3 (da) | 2001-09-19 | 2002-09-19 | VEGF til anvendelse ved behandling af lidelser i centralnervesystemet |
DK02798797.3T DK1443955T3 (da) | 2001-09-19 | 2002-09-19 | PDGF-BB til behandling af Parkinsons sygdom |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10179127.5T DK2266594T3 (da) | 2001-09-19 | 2002-09-19 | VEGF til anvendelse ved behandling af lidelser i centralnervesystemet |
Country Status (10)
Country | Link |
---|---|
US (2) | US7981863B2 (da) |
EP (3) | EP2289537A1 (da) |
AU (1) | AU2002334327B2 (da) |
CA (1) | CA2461176C (da) |
CY (1) | CY1113699T1 (da) |
DK (2) | DK2266594T3 (da) |
ES (2) | ES2546093T3 (da) |
HK (2) | HK1152243A1 (da) |
PT (2) | PT1443955E (da) |
WO (1) | WO2003024478A1 (da) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9694038B2 (en) * | 2000-04-06 | 2017-07-04 | Wayne P. Franco | Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs |
US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
CA2444624A1 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
KR20030093316A (ko) * | 2001-04-13 | 2003-12-06 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 혈관 내피 성장 인자 2 |
US7943376B2 (en) * | 2001-04-27 | 2011-05-17 | Stem Cell Therapuetics Inc. | Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells |
US20040214766A1 (en) * | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
WO2003069310A2 (en) * | 2002-02-14 | 2003-08-21 | Buck Institute | Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia |
GB0205772D0 (en) * | 2002-03-12 | 2002-04-24 | Gill Steven S | Catheter |
WO2003094965A2 (en) * | 2002-05-08 | 2003-11-20 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
US7998460B2 (en) * | 2003-04-17 | 2011-08-16 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of deficits in neurogenesis with anti-inflammatory agents |
WO2004093802A2 (en) * | 2003-04-17 | 2004-11-04 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of deficits in neurogenesis with anti-inflammatory agents |
WO2005025553A2 (en) * | 2003-09-12 | 2005-03-24 | Neuronova Ab | Treatment of disorders of nervous systemsystem with fty720 |
CA2539918A1 (en) * | 2003-09-23 | 2005-04-07 | Ludwig Institute For Cancer Research | Vege-cor vege-d materials and methods for stimulation of neural stem cells |
US20070269412A1 (en) | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
CA2550383A1 (en) * | 2003-12-19 | 2005-07-14 | Imclone Systems Incorporated | Methods and compositions for directing migration of neural progenitor cells |
EP2899278A1 (en) * | 2004-03-12 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | iRNA agents targeting VEGF |
RS51481B (en) * | 2004-05-27 | 2011-04-30 | Vib, Vzw | TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS |
WO2006055743A2 (en) * | 2004-11-18 | 2006-05-26 | Franco, Wayne | Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs |
EP1837034A4 (en) * | 2004-11-30 | 2009-08-05 | Anges Mg Inc | MEDICATION FOR ALZHEIMER'S DISEASE |
CA2589343A1 (en) * | 2004-12-01 | 2006-06-08 | Stem Cell Therapeutics Corporation | Platelet-derived growth factor-responsive neural precursor cells and progeny thereof |
NZ571568A (en) * | 2006-03-31 | 2010-11-26 | Alnylam Pharmaceuticals Inc | Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene |
AU2007240429A1 (en) | 2006-04-17 | 2007-11-01 | Ludwig Institute For Cancer Research Ltd | Methods and compositions for modulation of blood-neural barrier |
US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
US20080044847A1 (en) | 2006-06-23 | 2008-02-21 | Shusta Eric V | Blood-Brain Barrier Model |
CN100445373C (zh) * | 2006-12-04 | 2008-12-24 | 山东大学 | 黄樟素氧化物在内皮细胞与神经干细胞培养体系中的应用 |
DE102007019162A1 (de) * | 2007-04-20 | 2008-10-23 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Verwendung von EGFL7 zur Modulation von Zellen |
AU2009221775B2 (en) * | 2008-03-05 | 2015-05-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
ES2376930B1 (es) * | 2009-02-05 | 2013-01-24 | Universidad Del Pais Vasco | Método para el tratamiento de enfermedades neurodegenerativas. |
US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
EP2702410A2 (en) | 2011-04-29 | 2014-03-05 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
EP2529745A1 (en) * | 2011-06-01 | 2012-12-05 | Universität Heidelberg | VEGF-D/VEGFR mediated regulation of dendrites |
EP2714063B1 (en) * | 2011-06-01 | 2017-12-27 | Universität Heidelberg | Vegfr2/3-activating agent for use in the treatment of cognitive dysfunctions |
US9415090B2 (en) | 2011-06-01 | 2016-08-16 | Universität Heidelberg | VEGF-D/VEGFR2/3-mediated regulation of dendrites |
CA2877736C (en) | 2012-06-29 | 2021-12-07 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
RU2542385C2 (ru) * | 2012-08-31 | 2015-02-20 | Общество с ограниченной ответственностью "НекстГен" | Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека |
CA2933464A1 (en) * | 2013-12-09 | 2015-06-18 | Thomas Jefferson University | Use of abc drug efflux inhibitors in combination with anti-neurodegenerative drugs in the treatment of neurodegenerative disorders |
US10369329B2 (en) | 2014-01-30 | 2019-08-06 | Renishaw Plc | Neurosurgical apparatus and method |
EP3110974A4 (en) | 2014-02-24 | 2018-01-24 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
KR20200029627A (ko) * | 2014-03-12 | 2020-03-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
WO2016092453A1 (en) * | 2014-12-07 | 2016-06-16 | Ramot At Tel-Aviv University Ltd. | Prevention or reversal of apoe4 induced brain pathology by activation of vegf receptors |
GB201506052D0 (en) | 2015-04-09 | 2015-05-27 | Renishaw Plc | Movement disorder |
RU2612497C2 (ru) | 2015-05-26 | 2017-03-09 | Общество с ограниченной ответственностью "НекстГен" | Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf |
US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
EP3412296A4 (en) * | 2016-02-05 | 2019-09-11 | Kyungpook National University Industry-Academic Cooperation Foundation | PHARMACEUTICAL COMPOSITION COMPRISING STEM CELLS IN WHICH A VASCULAR ENDOTHELIUM GROWTH FACTOR IS OVEREXPRESSED AS AN ACTIVE INGREDIENT TO PREVENT OR TREAT NEURODEGENERATIVE DISEASE |
RU2639175C1 (ru) * | 2016-11-14 | 2017-12-20 | Общество с ограниченной ответственностью "НекстГен" | Способ индукции регенерации периферического нерва |
US20230033523A1 (en) * | 2021-07-30 | 2023-02-02 | The Research Foundation For The State University Of New York | Method of treating cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy (cadasil) |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5219759A (en) * | 1987-04-22 | 1993-06-15 | Chiron Corporation | Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors |
US4899919A (en) | 1988-04-01 | 1990-02-13 | Clumb Thomas E | Self energizing fastener system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
IT1237435B (it) * | 1989-12-14 | 1993-06-04 | Farmaco attivo nel ripristino della plasticita' neuronale. | |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6497872B1 (en) * | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
US6071889A (en) * | 1991-07-08 | 2000-06-06 | Neurospheres Holdings Ltd. | In vivo genetic modification of growth factor-responsive neural precursor cells |
US6294346B1 (en) * | 1991-07-08 | 2001-09-25 | Neurospheres Holdings, Ltd. | Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents |
US5980885A (en) * | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | Growth factor-induced proliferation of neural precursor cells in vivo |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU673659B2 (en) | 1991-11-25 | 1996-11-21 | Institute Of Molecular Biology, Inc. | Medicament for promoting growth of mammalian nerve |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
EP0802800B1 (en) * | 1993-08-12 | 2002-06-12 | Neurotech S.A. | Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
HU223438B1 (hu) * | 1995-03-02 | 2004-07-28 | Amrad Operations Pty. Ltd. | Új növekedési faktor és ezt kódoló génszekvencia |
US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5711316A (en) | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6165783A (en) * | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
CA2311729A1 (en) | 1998-01-23 | 1999-07-29 | Imclone Systems Incorporated | Purified populations of stem cells |
ES2313778T3 (es) | 1998-03-17 | 2009-03-01 | Genentech, Inc. | Polipeptidos homologos de vegf y de bmp1. |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
IL141687A0 (en) * | 1998-09-09 | 2002-03-10 | Scios Inc | Treatment of microvascular angiopathies |
US6432673B1 (en) * | 1998-12-07 | 2002-08-13 | Zymogenetics, Inc. | Growth factor homolog ZVEGF3 |
EP1187843A1 (en) * | 1999-06-03 | 2002-03-20 | Human Genome Sciences, Inc. | Angiogenic proteins and uses thereof |
MXPA02001719A (es) | 1999-08-18 | 2003-09-25 | Childrens Medical Center | METODOS, COMPOSICIONES Y EQUIPOS PARA PROMOVER LA RECUPERACION DEL DAnO AL SISTEMA NERVIOSO CENTRAL. |
JP4642303B2 (ja) | 1999-09-21 | 2011-03-02 | アンジェスMg株式会社 | 脳血管障害のための遺伝子治療 |
AU2631001A (en) | 2000-01-05 | 2001-07-16 | Zymogenetics Inc. | Novel fgf homolog zfgf11 |
US7582292B2 (en) * | 2000-02-26 | 2009-09-01 | Artecel, Inc. | Adipose tissue derived stromal cells for the treatment of neurological disorders |
DK1272208T3 (da) | 2000-04-12 | 2011-10-31 | Vib Vzw | Anvendelse af VEGF 165 og homologer til at behandle neuron-sygdomme |
US7943376B2 (en) * | 2001-04-27 | 2011-05-17 | Stem Cell Therapuetics Inc. | Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells |
US20040214766A1 (en) * | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
US20050032697A1 (en) * | 2003-06-12 | 2005-02-10 | Kari Alitalo | Heparin binding VEGFR-3 ligands |
EP2018184B1 (en) * | 2006-05-17 | 2013-09-11 | The Ludwig Institute for Cancer Research | Anti-VEGF-B antibody for the treatment or prophylaxis of diabetes type II or metabolic syndrome |
US20100135970A1 (en) * | 2006-10-27 | 2010-06-03 | Caritas St. Elizabeth Medical Center Of Boston, In | Methods for Reprogramming Adult Somatic Cells and Uses Thereof |
-
2002
- 2002-09-18 US US10/246,091 patent/US7981863B2/en not_active Expired - Fee Related
- 2002-09-19 CA CA2461176A patent/CA2461176C/en not_active Expired - Fee Related
- 2002-09-19 EP EP10179119A patent/EP2289537A1/en not_active Withdrawn
- 2002-09-19 AU AU2002334327A patent/AU2002334327B2/en not_active Ceased
- 2002-09-19 PT PT2798797T patent/PT1443955E/pt unknown
- 2002-09-19 DK DK10179127.5T patent/DK2266594T3/da active
- 2002-09-19 EP EP10179127.5A patent/EP2266594B1/en not_active Expired - Lifetime
- 2002-09-19 ES ES10179127.5T patent/ES2546093T3/es not_active Expired - Lifetime
- 2002-09-19 PT PT101791275T patent/PT2266594E/pt unknown
- 2002-09-19 EP EP02798797A patent/EP1443955B1/en not_active Expired - Lifetime
- 2002-09-19 WO PCT/IB2002/003998 patent/WO2003024478A1/en not_active Application Discontinuation
- 2002-09-19 DK DK02798797.3T patent/DK1443955T3/da active
- 2002-09-19 ES ES02798797T patent/ES2396545T3/es not_active Expired - Lifetime
-
2005
- 2005-02-12 HK HK11106377.7A patent/HK1152243A1/xx not_active IP Right Cessation
- 2005-02-12 HK HK05101145.7A patent/HK1068501A1/xx not_active IP Right Cessation
-
2011
- 2011-06-14 US US13/159,623 patent/US20120077741A1/en not_active Abandoned
-
2012
- 2012-12-12 CY CY20121101218T patent/CY1113699T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7981863B2 (en) | 2011-07-19 |
HK1152243A1 (en) | 2012-02-24 |
HK1068501A1 (en) | 2005-04-22 |
US20030203844A1 (en) | 2003-10-30 |
EP2289537A1 (en) | 2011-03-02 |
PT2266594E (pt) | 2015-08-05 |
WO2003024478A1 (en) | 2003-03-27 |
DK2266594T3 (da) | 2015-08-10 |
CY1113699T1 (el) | 2016-06-22 |
AU2002334327B2 (en) | 2006-05-04 |
EP1443955B1 (en) | 2012-09-12 |
CA2461176C (en) | 2013-11-05 |
EP2266594A1 (en) | 2010-12-29 |
US20120077741A1 (en) | 2012-03-29 |
ES2396545T3 (es) | 2013-02-22 |
EP2266594B1 (en) | 2015-05-27 |
CA2461176A1 (en) | 2003-03-27 |
WO2003024478A9 (en) | 2003-06-05 |
EP1443955A1 (en) | 2004-08-11 |
ES2546093T3 (es) | 2015-09-18 |
PT1443955E (pt) | 2012-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1443955T3 (da) | PDGF-BB til behandling af Parkinsons sygdom | |
NO20054640D0 (no) | Fremgangsmater for behandling av Parkinsons sykdom | |
DK1392287T3 (da) | Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom | |
EE200200716A (et) | Ühendid Alzheimeri tõve käitluseks | |
DK1303272T3 (da) | Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom | |
DK1343773T3 (da) | Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser | |
NO20035522D0 (no) | Kinuklidin-substituerte multisykliske heteroaryler for behandling av sykdom | |
DK3210637T3 (da) | Infusionssæt | |
NO20053115D0 (no) | Fremgangsmate for fremstilling av 2'-forgrenede nukleosider. | |
DK1383560T4 (da) | Infusionssæt | |
NO20035156L (no) | Fremgangsmåter for brønnbehandling | |
NO20034538L (no) | Anvendelsen av enantiomer ren escitalopram | |
DK1448205T3 (da) | Kombinationer til behandling af immunoinflammatoriske sygdomme | |
NO20042613L (no) | Ny anvendelse for behandling av gastroosofagial refluks | |
DE50113918D1 (de) | Quengel-Orthese | |
DK1268482T3 (da) | Pyranoindoler til behandling af glaukom | |
NO20042476L (no) | Anvendelse av desoxypeganin for behandling av klinisk depresjon | |
DK1200447T3 (da) | Oxazinocarbazoler til behandling af CNS-sygdomme | |
NO20043113L (no) | Fremgangsmate for behandling av benforstyrrelse | |
DK1468686T3 (da) | S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser | |
DK1373232T3 (da) | Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner | |
DE60207900D1 (de) | "Suspend"-Paketübertrager | |
DE60130812D1 (de) | Okularlinse | |
DE60134712D1 (de) | Regulierventil | |
ITPG20010047A1 (it) | Sesso piu' |